Premium
Tramadol/Acetaminophen Combination Tablets for the Treatment of Pain Associated with Osteoarthritis Flare in an Elderly Patient Population
Author(s) -
Rosenthal Norman R.,
Silverfield Joel C.,
Wu ShuChen,
Jordan Donna,
Kamin Marc
Publication year - 2004
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.2004.52108.x
Subject(s) - tramadol , medicine , acetaminophen , placebo , nausea , osteoarthritis , vomiting , adverse effect , anesthesia , population , analgesic , alternative medicine , environmental health , pathology
Objectives: To evaluate the efficacy and safety of adding tramadol 37.5 mg/acetaminophen (APAP) 325 mg combination tablets (tramadol/APAP) to existing therapy for painful osteoarthritis (OA) flare in a subset of elderly patients. Design: Randomized, double‐blind, placebo‐controlled, 10‐day add‐on study. Setting: Thirty outpatient centers. Participants: Of 308 patients with painful OA flare, a subset of 113 patients aged 65 and older. Measurements: Average daily pain intensity and pain relief scores for Days 1 through 5 and secondary quality‐of‐life measures and medication assessments. Methods: Patients received one or two tramadol/APAP tablets or placebo four times per day for 10 days during ongoing nonselective or cyclooxygenase (COX)‐2–selective nonsteroidal antiinflammatory drug (NSAID) therapy. Results: Tramadol/APAP (n=69) was significantly superior to placebo (n=44) for average daily pain intensity ( P =.034) and pain relief ( P =.010) for Days 1 through 5 and Days 1 through 10 ( P =.012 and P =.019, respectively). Tramadol/APAP had significantly better investigator ( P <.001) and patient ( P =.001) overall medication assessments and significantly better scores on three of four Western Ontario and McMaster Universities Osteoarthritis Index measures ( P ≤.027). Most common adverse events with tramadol/APAP were nausea (18.8%), vomiting (13.0%), dizziness (11.6%), and constipation (4.3%), with an incidence similar to that of the overall study population. Mean daily dose of tramadol/APAP was 4.5 tablets (168 mg/1,458 mg). Conclusion: Tramadol/APAP add‐on therapy effectively managed painful OA flare in this elderly subset and was generally well tolerated.